schizophrenia

Boehringer's phase 3 schizophrenia program misses primary goal
Fierce Biotech
Thu, 01/16/25 - 09:39 pm
Boehringer Ingelheim
schizophrenia
clinical trials
iclepertin
LB Pharma's twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push
Fierce Biotech
Wed, 01/8/25 - 11:19 am
LB Pharma
schizophrenia
clinical trials
Sanofi
LB-102
Teva looks to peel back the onion on CNS, mental health conditions as it works on long-acting schizophrenia candidate
Fierce Pharma
Wed, 01/1/25 - 10:48 pm
Teva Pharmaceutical
TEV 749
schizophrenia
Zyprexa
Reviva’s antipsychotic shows promise against schizophrenia symptoms in year-long study
Fierce Biotech
Mon, 12/16/24 - 11:29 am
Bristol Myers Squibb
Cobenfy
Reviva
schizophrenia
brilaroxazine
clinical trials
Eisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-on
Fierce Biotech
Sun, 12/15/24 - 10:48 pm
Newron Pharma
Eisai
schizophrenia
evenamide
Advantage BMS as AbbVie drug fails schizophrenia trials
Pharmaphorum
Mon, 11/11/24 - 11:24 am
AbbVie
emraclidine
schizophrenia
Cerevel Therapeutics
clinical trials
Bristol Myers Squibb
Teva’s long-lasting schizophrenia injectable shines in Phase III
Clinical Trials Arena
Mon, 11/4/24 - 07:02 pm
Teva Pharmaceutical
clinical trials
schizophrenia
TEV-479
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
Fierce Pharma
Mon, 10/7/24 - 11:16 am
Bristol Myers Squibb
KarXT
Cobenfy
schizophrenia
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Medical Marketing and Media
Mon, 09/30/24 - 09:28 am
Bristol Myers Squibb
FDA
schizophrenia
Cobenfy
FDA eyes first schizophrenia drug shift in decades
Axios
Thu, 09/26/24 - 11:02 am
Bristol Myers Squibb
FDA
KarXT
schizophrenia
Teva touts safety profile of once-monthly schizophrenia therapy
Clinical Trials Arena
Mon, 09/23/24 - 11:17 am
Teva Parmceuticals
TEV-749
Olanzapine
schizophrenia
Neurocrine's bid to save schizophrenia prospect fails
Fierce Biotech
Fri, 09/13/24 - 11:14 am
Neurocrine Biosciences
schizophrenia
clinical trials
luvadaxistat
3 FDA approval dates to watch in the year’s final push
Pharma Voice
Wed, 09/11/24 - 11:39 am
FDA
Bristol Myers Squibb
KarXT
schizophrenia
Regeneron
Sanofi
Dupixent
COPD
BridgeBio
acoramidis
ATTR cardiomyopathy
Neurocrine's drug cuts schizophrenia symptoms in mid-stage study
Reuters
Wed, 08/28/24 - 11:42 am
Neurocrine Biosciences
schizophrenia
clinical trials
NBI-1117568
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
Pharma Voice
Mon, 08/19/24 - 09:58 am
Bristol Myers Squibb
KarXT
FDA
schizophrenia
AbbVie
5 Neuro Data Readouts to Watch in the Second Half of 2024
BioSpace
Mon, 07/15/24 - 11:43 am
neurology
clinical trials
Athira Pharma
fosgonimeton
Alzheimer's disease
AbbVie
Cerevel Therapeutics
emraclidine
schizophrenia
Neumora Therapeutics
major depressive disorder
navacaprant
Amylx
AMX003
Wolfram syndrome
Vigil Neuroscience
iluzanebart
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
Teva, Medincell's schizophrenia drug succeeds in late-stage study
Yahoo/Reuters
Wed, 05/8/24 - 11:11 am
Teva Pharmaceutical
MedinCell
schizophrenia
clinical trials
TEV-749
As BMS announces major cuts, its Karuna deal looks poised to drive growth
Pharma Voice
Tue, 04/30/24 - 08:29 am
Karuna Therapeutics
schizophrenia
Bristol Myers Squibb
clinical trials
KarXT
Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits
Fierce Biotech
Mon, 04/15/24 - 11:00 am
Neumora Therapeutics
schizophrenia
FDA
clinical trials
NMRA-266

Pages